Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics innovator developing PCR-based testing solutions through its patented Co-Primers™ technology. This page serves as the definitive source for verified company news and announcements, providing stakeholders with timely updates on developments impacting global healthcare diagnostics.
Investors and industry professionals will find curated press releases covering financial results, regulatory milestones, product launches, and strategic partnerships. Our aggregation includes updates on CODX's expanding test menu (including tuberculosis and respiratory disease diagnostics), manufacturing expansions, and progress toward decentralized testing solutions through the Co-Dx™ platform.
Key resources include earnings call transcripts, FDA clearance announcements, and analysis of emerging market initiatives like the CoSara Diagnostics joint venture in India. All content is organized chronologically demonstrate the company's trajectory while maintaining compliance with financial disclosure standards.
Bookmark this page for direct access to primary source materials that inform investment decisions and industry analysis. Check regularly for updates on CODX's contributions to accessible, high-accuracy diagnostic testing worldwide.
Co-Diagnostics (Nasdaq: CODX) announced the closing of a registered direct offering of 12,727,272 shares of common stock (or pre-funded warrants) at $0.55 per share, generating gross proceeds of approximately $7.0 million before placement agent fees and offering expenses. The company said it intends to use the proceeds for working capital and general corporate purposes. Maxim Group acted as sole placement agent. The securities were offered under a shelf registration statement on Form S-3 declared effective by the SEC on April 6, 2023, and a prospectus supplement related to the Offering was filed with the SEC.
Co-Diagnostics (Nasdaq: CODX) announced a registered direct offering priced at-the-market to sell 12,727,272 shares of common stock (or pre-funded warrants) at $0.55 per share, with gross proceeds of approximately $7.0 million. The Company said proceeds will be used for working capital and general corporate purposes.
The Offering is expected to close on or about October 29, 2025, subject to customary closing conditions. Maxim Group is acting as sole placement agent. The securities are offered under a shelf registration statement on Form S-3 declared effective April 6, 2023, and a prospectus supplement will be filed with the SEC.
Co-Diagnostics (NASDAQ: CODX) signed a definitive joint venture agreement with Arabian Eagle to form CoMira Diagnostics in the Kingdom of Saudi Arabia to research, develop, manufacture, assemble, distribute, and commercialize Co-Dx technologies across KSA and 18 additional MENA countries. CoMira will pursue SFDA clearance to facilitate regional market entry and receive an exclusive license to manufacture and commercialize Co-Dx IP, including the upcoming Co-Dx PCR point-of-care platform. Infectious-disease tests slated for clinical evaluations before the end of 2025 include tuberculosis, an 8-type HPV multiplex, and a respiratory multiplex for influenza A/B, COVID-19, and RSV. The platform remains subject to regulatory review and is not yet available for sale.
Co-Diagnostics (NASDAQ: CODX) said its executive leadership team will attend and host a booth at Global Health Exhibition 2025 in Riyadh, KSA, on October 27–30, 2025. Attendees listed include CEO Dwight Egan, President Richard Abbott, Chief Commercialization and Strategy Officer Seth Egan, other department heads, and board member Eugene Durenard.
The company will showcase its Co-Dx infectious disease PCR products and the upcoming Co-Dx PCR point-of-care platform at Booth #H3.L17. The announcement follows a September 16 MOU exploring a joint venture to develop, manufacture, and sell Co-Dx IP across the Middle East and North Africa. The Co-Dx PCR platform is subject to regulatory review and not available for sale.
Co-Diagnostics (Nasdaq: CODX) announced development of a proprietary sample preparation instrument for its point-of-care Co-Dx PCR MTB test, designed for low-cost, user-friendly sample processing in resource-limited settings. The device supports sputum and a novel tongue swab method, uses single-button operation with no measuring tools, and includes a built-in safety feature to inactivate live organisms. Clinical evaluations in India for the MTB test are expected to begin before year-end 2025. Manufacturing is anticipated with Systronics under India’s "Make in India" initiative.
Co-Diagnostics (Nasdaq: CODX) announced it will participate in the 2025 Maxim Growth Summit on October 22-23 at The Hard Rock Hotel NYC. The company said it will hold one-on-one meetings with institutional investors and meet with senior Maxim analysts during the event.
The summit features keynote speakers Larry Kudlow and Christopher Ruddy, roundtable discussions across sectors including biotechnology and artificial intelligence, and sessions moderated by Maxim Research Analysts. For agenda details, attendees are directed to the Maxim Growth Summit website.
Co-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, announced its participation in the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will deliver a webcast presentation at 4:15 p.m. ET and conduct one-on-one meetings with institutional investors.
The presentation will be accessible through the conference website and will be available for replay afterward. Investors can find the presentation slides on the company's investor relations website and schedule one-on-one meetings through Lytham Partners.
Co-Diagnostics (NASDAQ:CODX) has completed its previously announced registered direct offering, raising $3.8 million in gross proceeds. The offering involved the sale of 9,619,000 shares of common stock priced at $0.40 per share, conducted at-the-market under Nasdaq rules.
The company plans to utilize the proceeds for working capital and general corporate purposes. Maxim Group LLC served as the sole placement agent for the offering, which was executed under an effective shelf registration statement on Form S-3.
Co-Diagnostics (NASDAQ:CODX) has announced a registered direct offering of 9,619,000 shares of common stock priced at $0.40 per share, aiming to raise approximately $3.8 million in gross proceeds. The offering is priced at-the-market under Nasdaq rules and is expected to close around September 18, 2025.
The molecular diagnostics company plans to use the proceeds for working capital and general corporate purposes. Maxim Group LLC is serving as the sole placement agent for the offering, which is being conducted under an effective S-3 shelf registration statement.
Co-Diagnostics (NASDAQ:CODX) has signed a strategic Memorandum of Understanding (MOU) with a partner in Saudi Arabia to establish a joint venture for manufacturing and distributing its Co-Dx™ PCR platform across the Middle East and North Africa (MENA) region.
The planned JV aligns with Saudi Arabia's Vision 2030 initiatives and follows a similar model to CODX's Indian joint venture, CoSara Diagnostics. The Saudi partner will provide local operational support, infrastructure, personnel, and regulatory expertise throughout the MENA region. Saudi Arabia represents one of the largest international markets for CODX's Logix Smart® tests.
The Co-Dx PCR platform, including PCR Home™ and PCR Pro™, is currently pending regulatory review and is not yet available for sale.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
